(UroToday.com) Following the proffered paper presentation from Dr. Nicholas James of the long-term data assessing abiraterone acetate in patients with hormone-sensitive metastatic prostate cancer, Dr. Maria De Santis discussed the accumulating data and experience in the treatment of metastatic naïve/sensitive prostate cancer.